AMEERA-5: A Randomized, Double-Blind Phase III Study of Amcenestrant + Palbociclib vs Letrozole + Palbociclib for Previously Untreated ER+/HER2- Advanced Breast Cancer
Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.